At InkVivo we combine our patented biomaterial platform with our advanced manufacturing approach to produce systems that ensure localised and temporal controlled release of active ingredients (e.g., small molecules, biologics, and micronutrients). We provide tailored solutions for several clinical challenges in the pharma and nutraceutical field. Initially, we focus on gastroretentive drug delivery systems tackling the markets of micronutrients anemia and obesity.
InkVivo offers patients more effective treatments that require less frequent administration and that minimise side effects. To our industrial partners we offer an effective strategy to develop novel therapies (e.g., co-formulation of drugs), and to reformulate and extend the lifecycle of existing products.
More than 20 Swiss biotech companies to exhibit at Bio Europe (startupticker.ch)
InkVivo Technologies secures CHF 1.1 million in pre-seed funding to advance polymer drug delivery platform (venturelab.swiss)
InkVivo Technologies secures CHF 1.1 million (startupticker.ch)
Venture Leaders Biotech 2025 connects Swiss science with the US biotech market (venturelab.swiss)
InkVivo: The Venture Leader Biotech enhancing drug delivery systems (venturelab.swiss)
Venture Leaders Biotech 2025 kick off at Swiss Biotech Day ahead of Boston roadshow (venturelab.swiss)
Venture Leaders Biotech 2025 cohort revealed (startupticker.ch)
Venture Leaders Biotech 2025: 10 innovative startups selected for Boston roadshow (venturelab.swiss)
The most promising Swiss biotech startups and scale-ups of 2024, according to investors (TOP 100)
Talent Kick expands program following two successful editions (startupticker.ch)